Stephen LaHue Cartt insider trades: Asterias Biotherapeutics (AST) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Stephen reports to the SEC
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 30, 2016 | AST | ↑ Buy | 10,000 | $2.40 | $24K | Direct | Jul 1, 2016 (1d) |
| Jun 10, 2016 | AST | ↑ Buy | 50,000 | $2.93 | $147K | Direct | Jun 13, 2016 (3d) |
| Aug 18, 2015 | BTX | ↑ Buy | 75,000 | $2.80 | $210K | Direct | Aug 18, 2015 (0d) |
| Nov 2, 2012 | QCOR | ↑ Buy | 10,000 | $24.17 | $242K | Direct | Nov 6, 2012 (4d) |
| Nov 8, 2011 | QCOR | ↓ Sell | 8,100 | $42.75 | $346K | Direct | Nov 10, 2011 (2d) |
| Oct 31, 2011 | QCOR | ↓ Sell | 164,286 | $41.55 | $6.8M | Direct | Nov 1, 2011 (1d) |
| Aug 15, 2011 | QCOR | ↓ Sell | 47,155 | $31.50 | $1.5M | Direct | Aug 17, 2011 (2d) |
| Aug 11, 2011 | QCOR | ↓ Sell | 110,968 | $31.04 | $3.4M | Direct | Aug 12, 2011 (1d) |
| Aug 4, 2011 | QCOR | ↓ Sell | 25,513 | $30.17 | $770K | Direct | Aug 8, 2011 (4d) |
| May 16, 2011 | QCOR | ↓ Sell | 149,487 | $22.36 | $3.3M | Direct | May 17, 2011 (1d) |
| Aug 4, 2009 | QCOR | ↓ Sell | 250,000 | $6.08 | $1.5M | Direct | Aug 5, 2009 (1d) |
| Dec 10, 2008 | QCOR | ↓ Sell | 100,000 | $9.50 | $950K | Direct | Dec 12, 2008 (2d) |
| May 30, 2008 | QCOR | ↓ Sell | 100,000 | $5.30 | $530K | Direct | Jun 3, 2008 (4d) |
| Mar 18, 2008 | QSC | ↓ Sell | 100,000 | $4.01 | $401K | Direct | Mar 20, 2008 (2d) |
| Dec 12, 2007 | QSC | ↓ Sell | 89,202 | $5.79 | $517K | Direct | Dec 12, 2007 (0d) |
| Dec 10, 2007 | QSC | ↓ Sell | 35,400 | $6.00 | $212K | Indirect | Dec 12, 2007 (2d) |
| Oct 31, 2005 | QSC | ↑ Buy | 35,400 | $0.64 | $23K | Held by the Cartt Family Trust | Nov 2, 2005 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Stephen LaHue Cartt's insider trades
Stephen LaHue Cartt is an insider at Asterias Biotherapeutics (AST). Since Oct 31, 2005, Stephen has reported 5 open-market purchases worth $645K and 12 sales worth $20.3M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (17 filings), option exercises (10 filings), shares withheld for taxes (4 filings), shares returned to the company (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AST insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.